Antipsychotics Induced Reproductive Toxicity by Stimulating Oxidative Stress: A Comparative in Vivo and in Silico Study

Abstract

The pathophysiological mechanism behind the link between antipsychotic drugs and sexual dysfunction is still unknown. The goal of this research is to compare the potential effects of antipsychotics on the male reproductive system. Fifty rats were randomly assigned into the five groups indicated: Control, Haloperidol, Risperidone, Quetiapine and Aripiprazole. Sperm parameters were significantly impaired in all antipsychoticstreated groups. Haloperidol and Risperidone significantly decreased the level of testosterone. All antipsychotics had significantly reduced inhibin B level. A significant reduction was observed in SOD activity in all antipsychotics-treated groups. While GSH levels diminished, MDA levels were rising in the Haloperidol and Risperidone groups. Also, the GSH level was significantly elevated in the Quetiapine and Aripiprazole groups. By causing oxidative stress and altering hormone levels, Haloperidol and Risperidone are damaging to male reproductivity. This study represents useful starting point for exploring further aspects of the underlying mechanisms reproductive toxicity of antipsychotics.

Psychiatric Disorders During Pregnancy and Postpartum Period: A Guide For Perinatal Interview

“…Antipsychotics have been used for the treatment of psychosis for decades, and their effects on the reproductive system have been investigated. 95 Recently, the results of an extensive cohort study on antipsychotic use have been published, and it has been reported that the use of antipsychotics in general during pregnancy is not directly related to malformation or neurodevelopmental disorder, except for the data of aripiprazole and olanzapine that require further research. 96 , 97 When a major congenital anomaly was evaluated, the risk was found to be 2.7% in babies of pregnant women who were not exposed to any antipsychotics, 4.3% in pregnant women using atypical antipsychotics, and 3.1% in babies using first-generation antipsychotics.…”